385 related articles for article (PubMed ID: 24262196)
1. Modeling Lewy pathology propagation in Parkinson's disease.
Luk KC; Lee VM
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S85-7. PubMed ID: 24262196
[TBL] [Abstract][Full Text] [Related]
2. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
3. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Uchihara T; Giasson BI
Acta Neuropathol; 2016 Jan; 131(1):49-73. PubMed ID: 26446103
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease from the gut.
Liddle RA
Brain Res; 2018 Aug; 1693(Pt B):201-206. PubMed ID: 29360467
[TBL] [Abstract][Full Text] [Related]
6. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.
Seidel K; Mahlke J; Siswanto S; Krüger R; Heinsen H; Auburger G; Bouzrou M; Grinberg LT; Wicht H; Korf HW; den Dunnen W; Rüb U
Brain Pathol; 2015 Mar; 25(2):121-35. PubMed ID: 24995389
[TBL] [Abstract][Full Text] [Related]
7. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
8. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
[TBL] [Abstract][Full Text] [Related]
9. Formation and development of Lewy pathology: a critical update.
Jellinger KA
J Neurol; 2009 Aug; 256 Suppl 3():270-9. PubMed ID: 19711116
[TBL] [Abstract][Full Text] [Related]
10. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
11. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
12. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
13. Spreading of alpha-synuclein - relevant or epiphenomenon?
Killinger BA; Kordower JH
J Neurochem; 2019 Sep; 150(5):605-611. PubMed ID: 31152606
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
15. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
Lashuel HA
Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
[TBL] [Abstract][Full Text] [Related]
16. The Lewy body in Parkinson's disease and related neurodegenerative disorders.
Wakabayashi K; Tanji K; Odagiri S; Miki Y; Mori F; Takahashi H
Mol Neurobiol; 2013 Apr; 47(2):495-508. PubMed ID: 22622968
[TBL] [Abstract][Full Text] [Related]
17. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?
Chartier S; Duyckaerts C
Cell Tissue Res; 2018 Jul; 373(1):149-160. PubMed ID: 29869713
[TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
19. Prion-like propagation of pathology in Parkinson disease.
Volpicelli-Daley L; Brundin P
Handb Clin Neurol; 2018; 153():321-335. PubMed ID: 29887143
[TBL] [Abstract][Full Text] [Related]
20. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
